FDA Adds Contrast Agent Label Warning



The U.S. Food and Drug Administration has set label requirements for gadolinium-based contrast agents used in MR imaging to minimize causing the rare but serious kidney dysfunction condition called nephrogenic systemic fibrosis.


Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below:

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.